ATOSSA THERAPEUTICS, INC.
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(18,080) | $(15,141) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation | 1,537 | 1,359 |
| Depreciation | 8 | 8 |
| Changes in operating assets and liabilities: | ||
| Prepaid materials | 68 | (1,377) |
| Prepaid expenses and other current assets | (665) | 90 |
| Other assets | 711 | (10) |
| Accounts payable | (2,317) | 1,331 |
| Accrued expenses | 73 | 1,281 |
| Payroll liabilities | (586) | (808) |
| Other current liabilities | 26 | 49 |
| Net cash used in operating activities | (19,225) | (13,218) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of property and equipment | — | (9) |
| Net cash used in investing activities | — | (9) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common stock and warrants | 4,500 | — |
| Offering costs for common stock and warrant issuance | (501) | — |
| Proceeds from issuance of common stock under the ATM program, net of issuance costs | 21 | — |
| Net cash provided by financing activities | 4,020 | — |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (15,205) | (13,227) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE | 41,409 | 71,194 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE | $26,204 | $57,967 |
| RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | ||
| Cash and cash equivalents | $26,094 | $57,857 |
| Restricted cash | 110 | 110 |
| Total cash, cash equivalents and restricted cash | $26,204 | $57,967 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.